Tag

Emraclidine

All articles tagged with #emraclidine

pharmaceuticals1 year ago•2 min saved

AbbVie's Schizophrenia Drug Fails, Boosting Bristol Myers' Stock

AbbVie's $8.7 billion acquisition of Cerevel Therapeutics has hit a setback as its schizophrenia drug candidate, emraclidine, failed two phase 2 trials, missing primary endpoints and showing no significant improvement over placebo. This failure benefits rival Bristol Myers Squibb, whose stock rose as AbbVie's fell. Despite the setback, AbbVie notes other promising candidates from the Cerevel acquisition, including a Parkinson's disease treatment that recently succeeded in phase 3 trials.

via Fierce Biotech|

#abbvie #bristol-myers-squibb #clinical-trials

health1 year ago•1 min saved

AbbVie's Schizophrenia Drug Fails Trials, Boosting Bristol Myers Stock

AbbVie's experimental schizophrenia drug, emraclidine, acquired through a $9 billion deal with Cerevel Therapeutics, failed to show significant patient improvement in Phase 2 trials. The drug did not outperform a placebo on the Positive and Negative Syndrome Scale (PANSS), leading AbbVie to reassess its next steps.

via STAT|

#abbvie #cerevel-therapeutics #clinical-trials

health1 year ago•6 min saved

AbbVie Shares Plummet After Schizophrenia Drug Trials Disappoint

AbbVie announced that its Phase 2 EMPOWER trials for emraclidine, a potential treatment for schizophrenia, did not meet the primary endpoint of significantly reducing symptoms compared to placebo. Despite the setback, emraclidine was well-tolerated, and AbbVie remains committed to advancing its neuroscience pipeline. The company continues to analyze the data to determine future steps in developing treatments for psychiatric and neurological disorders.

via AbbVie|

#abbvie #clinical-trials #emraclidine